Home » Newsletters » BioWorld Science

BioWorld Science

May 25, 2016

View Archived Issues

Mixed results for KRP-203 in ulcerative colitis phase II trial

Linaclotide shows preclinical potential for bladder hyperactivity

Amgen's FOLR1-BiTE antibody constructs target folate receptor 1 in ovarian tumors

PF-04236921 effective in phase II trial for Crohn's disease

FDA approves Flucelvax Quadrivalent

Ironwood's IWP-953 for ocular hypertension

MorphoSys and MD Anderson form alliance to develop anticancer antibodies

Eli Lilly initiates phase I trial of LY-3298176 for type 2 diabetes

FDA approves Janssen Pharmaceutical's Invokamet line extension

Dart NeuroScience patents glycine transporter 1 inhibitors

Roche describes beta-secretase inhibitors

Dart NeuroScience discloses PDE2A inhibitors

Janssen Pharmaceutica reports RORgammaT receptor modulators

Merck & Co. patents orexin receptor antagonists

FDA clears IND application for Abeona's ABO-101

Theratechnologies presents preliminary primary endpoint results from phase III ibalizumab trial

New company Thunderbolt Pharma acquires rights to Astellas' BAFF/APRIL antagonist program

Hillhurst Biopharmaceuticals receives grant for HBI-002 in sickle cell disease

Big DNA becomes Iceni Pharmaceuticals with focus on repurposing cancer therapies

Monsanto labels Bayer's acquisition proposal "incomplete and financially inadequate"

InDex Pharmaceuticals receives grant for preclinical development of DIMS compounds

PDL BioPharma commits to equity investment in Noden Pharma

FDA approves Roche CMV test for use in hematopoietic stem cell transplant recipients

GM-604 shows safety and efficacy in patients with ALS worldwide

Asterias Biotherapeutics reports long-term results of phase I study of AST-OPC1

Novartis expands access to Ensemble Therapeutics' IL-17 antagonist program

AstraZeneca launches Tagrisso in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...